117 related articles for article (PubMed ID: 26168957)
1. Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma.
Mao S; Yang W; Ai L; Li Z; Jin J
Tumour Biol; 2015 Dec; 36(12):9903-8. PubMed ID: 26168957
[TBL] [Abstract][Full Text] [Related]
2. [Expression of Smad4 and transforming growth factor-beta1, transforming growth factor-beta receptor II in cholangiocarcinoma tissue and its biological significance].
Zhang BY; Zhang JY; Zhao K; Wu LQ
Zhonghua Wai Ke Za Zhi; 2005 Jul; 43(13):846-9. PubMed ID: 16083599
[TBL] [Abstract][Full Text] [Related]
3. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.
Pannu J; Gore-Hyer E; Yamanaka M; Smith EA; Rubinchik S; Dong JY; Jablonska S; Blaszczyk M; Trojanowska M
Arthritis Rheum; 2004 May; 50(5):1566-77. PubMed ID: 15146427
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Osada H; Tatematsu Y; Masuda A; Saito T; Sugiyama M; Yanagisawa K; Takahashi T
Cancer Res; 2001 Nov; 61(22):8331-9. PubMed ID: 11719467
[TBL] [Abstract][Full Text] [Related]
5. Silencing of the transforming growth factor-beta (TGFbeta) receptor II by Kruppel-like factor 14 underscores the importance of a negative feedback mechanism in TGFbeta signaling.
Truty MJ; Lomberk G; Fernandez-Zapico ME; Urrutia R
J Biol Chem; 2009 Mar; 284(10):6291-300. PubMed ID: 19088080
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of TβRII Expression in Breast Cancer.
Gao N; Zhai Q; Li Y; Huang K; Bian D; Wang X; Liu C; Xu H; Zhang T
PLoS One; 2015; 10(11):e0141412. PubMed ID: 26551005
[TBL] [Abstract][Full Text] [Related]
7. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor up-regulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblasts.
Yamane K; Ihn H; Tamaki K
Arthritis Rheum; 2003 Jun; 48(6):1652-66. PubMed ID: 12794834
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
10. CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.
Yokoyama M; Ichinoe M; Okina S; Sakurai Y; Nakada N; Yanagisawa N; Jiang SX; Numata Y; Umezawa A; Miyazaki K; Higashihara M; Murakumo Y
Int J Hematol; 2017 May; 105(5):614-622. PubMed ID: 28032275
[TBL] [Abstract][Full Text] [Related]
11. The long non-coding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large B-cell lymphoma.
Zhao S; Fang S; Liu Y; Li X; Liao S; Chen J; Liu J; Zhao L; Li H; Zhou W; Shen W; Dong X; Xiang R; Wang L; Zhao Y
Oncotarget; 2017 May; 8(21):34374-34386. PubMed ID: 28423735
[TBL] [Abstract][Full Text] [Related]
12. TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation.
Munoz O; Fend F; de Beaumont R; Husson H; Astier A; Freedman AS
Leukemia; 2004 Dec; 18(12):2015-25. PubMed ID: 15470494
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients.
Tokunaga H; Lee DH; Kim IY; Wheeler TM; Lerner SP
Clin Cancer Res; 1999 Sep; 5(9):2520-5. PubMed ID: 10499628
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors.
Kidd M; Eick G; Shapiro MD; Camp RL; Mane SM; Modlin IM
Cancer; 2005 Jan; 103(2):229-36. PubMed ID: 15599934
[TBL] [Abstract][Full Text] [Related]
15. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
16. The role of miR‑370 in fibrosis after myocardial infarction.
Yuan H; Gao J
Mol Med Rep; 2017 May; 15(5):3041-3047. PubMed ID: 28350072
[TBL] [Abstract][Full Text] [Related]
17. Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells.
Zhang H; Shaw AR; Mak A; Letarte M
J Immunol; 1996 Jan; 156(2):564-73. PubMed ID: 8543807
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
[TBL] [Abstract][Full Text] [Related]
19. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.
Arcaini L; Rossi D; Lucioni M; Nicola M; Bruscaggin A; Fiaccadori V; Riboni R; Ramponi A; Ferretti VV; Cresta S; Casaluci GM; Bonfichi M; Gotti M; Merli M; Maffi A; Arra M; Varettoni M; Rattotti S; Morello L; Guerrera ML; Sciarra R; Gaidano G; Cazzola M; Paulli M
Haematologica; 2015 Feb; 100(2):246-52. PubMed ID: 25381127
[TBL] [Abstract][Full Text] [Related]
20. Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers.
Takenoshita S; Mogi A; Tani M; Osawa H; Sunaga H; Kakegawa H; Yanagita Y; Koida T; Kimura M; Fujita KI; Kato H; Kato R; Nagamachi Y
Oncol Rep; 1998; 5(2):367-71. PubMed ID: 9468559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
